News about Market

Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea

Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea

Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.

Market | 17/09/2025 | By Dineshwori 539

Sagent Pharmaceuticals Enters Ophthalmic Market, Launches Travoprost Ophthalmic Solution

Sagent Pharmaceuticals Enters Ophthalmic Market, Launches Travoprost Ophthalmic Solution

Travoprost is the first ophthalmic product offering in Sagent's portfolio, with plans to launch more products in the coming year.

Market | 16/09/2025 | By Dineshwori 235

REFCOLD India 2025 to Showcase Cold-Chain Innovations in Delhi

REFCOLD India 2025 to Showcase Cold-Chain Innovations in Delhi

REFCOLD India 2025 will feature specialised platforms such as the innovation zone, demo zone, product launch pad, celebrating the next generation of engineers through a global student poster competition and outdoor displays, spotlighting next-generation technologies across multiple refrigeration applications.

Market | 16/09/2025 | By Dineshwori 411

B Braun Acquires True Digital Surgery

B Braun Acquires True Digital Surgery

Before the acquisition, B Braun held a minority stake in TDS. The decision to fully acquire TDS allows B Braun's surgical division Aesculap to secure the valuable expertise of the TDS team, ensuring the continuous technological advancement of Aesculap AEOS.

Market | 13/09/2025 | By Dineshwori 274

Pulnovo Wins Two IDE Approvals for PADN Trials with CMS Coverage

Pulnovo Wins Two IDE Approvals for PADN Trials with CMS Coverage

Following the FDA's BDD designation granted in 2021 for Group- I, II and IV, the newly-obtained IDE approvals for Pulnovo Medical’s PADN with CMS coverage will advance clinical studies targeting Groups-I and II into the IDE stage.

Market | 13/09/2025 | By Dineshwori 203

Indian Pharma Exporters Face Delayed Payments from Cairo-Based API importer, Embassy Cautions

Indian Pharma Exporters Face Delayed Payments from Cairo-Based API importer, Embassy Cautions

The Embassy of India in Cairo has advised Indian pharmaceutical exporters to exercise caution when dealing with an Egyptian company, citing significant delays in payment settlements.

Market | 13/09/2025 | By Dineshwori 355

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Avidity Biosciences will use the funds, along with existing reserves, to advance late-stage clinical programmes, prepare for potential launches, expand commercial infrastructure, progress its AOC platform, and for general corporate needs.

Market | 13/09/2025 | By Dineshwori 340

LB Pharmaceuticals Raises 285 Million USD in Biotech IPO, Valued at Over 300 Million

LB Pharmaceuticals Raises 285 Million USD in Biotech IPO, Valued at Over 300 Million

LB Pharmaceuticals has raised 285 million USD in its initial public offering in the United States, the biotechnology company has confirmed, marking the first major biotech IPO since February. The New York-based firm sold 19 million shares at 15 USD apiece, pricing the offering within its earlier indicated range of 14 to 16 USD per share.

Market | 12/09/2025 | By Darshana 135

Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition

Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition

Europe currently dominates the global net-zero pharma supply chain market supported by strict climate regulations, while Asia-Pacific is the fastest-growing region, spurred by new government-led sustainability policies.

Market | 11/09/2025 | By Dineshwori 1167

GTCR to Acquire Zentiva in 4.8 Billion USD Private Equity Buy-out

GTCR to Acquire Zentiva in 4.8 Billion USD Private Equity Buy-out

Private equity firm GTCR has entered into an agreement to acquire Zentiva, a pharmaceutical company headquartered in Europe, for approximately 4.8 billion USD (roughly 4.4 billion EURO based on current exchange rates).

Market | 11/09/2025 | By Darshana 182

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members